Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isoquinolinium compound, pharmaceutical composition containing the same, preparation and use thereof

A compound and isoquinoline technology, applied in the field of isoquinoline compounds or their salts, can solve the problems of strong cardiac contractility inhibition and the like, and achieve the effects of good antiarrhythmic activity and enhanced myocardial contractility

Active Publication Date: 2009-07-01
JIANGSU KANION PHARMA CO LTD +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The problem to be solved by the present invention is to overcome the defect that the existing antiarrhythmic drugs have a strong inhibitory effect on cardiac contractility, and provide a new antiarrhythmic drug that has antiarrhythmic activity and exhibits a certain enhancement effect on myocardial contractility. The isoquinoline compound or its salt, and its pharmaceutical composition, preparation method and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isoquinolinium compound, pharmaceutical composition containing the same, preparation and use thereof
  • Isoquinolinium compound, pharmaceutical composition containing the same, preparation and use thereof
  • Isoquinolinium compound, pharmaceutical composition containing the same, preparation and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 6,7-methylenedioxy-1-(2-furylmethyl)-3,4-dihydroisoquinoline

[0039] Dissolve 2.59g (10mmol) N-2-furanoacetyl-3,4-methylenedioxyphenethylamine in 60ml chloroform, add 2ml (20mmol) POCl dropwise 3 , after the addition, heat to reflux until the point plate reaction shows that the reactant is completely consumed (about 3 hours), and the excess POCl is evaporated under reduced pressure. 3and chloroform, the residue was washed with 1:1 benzene-hexane, solidified, and the crude product was collected by filtration, recrystallized from methanol-ether (volume ratio 1:1) to obtain 6,7-methylenedioxy-1-(2 -furylmethyl)-3,4-dihydroisoquinoline, yield 95%.

Embodiment 2

[0040] Example 2 6,7-methylenedioxy-1-(2-furylmethyl)-3,4-dihydroisoquinoline hydrochloride

[0041] Dissolve 2.59g (10mmol) N-2-furanoacetyl-3,4-methylenedioxyphenethylamine in 60ml chloroform, add 1ml (10mmol) POCl dropwise 3 , the addition is completed, heated to 50 ° C, until the point plate reaction shows that the reactants are completely consumed (about 3 hours), and the excess POCl is evaporated under reduced pressure 3 and chloroform, the residue was washed with 1:1 benzene-hexane, solidified, and the crude product was collected by filtration, recrystallized from methanol-ether (volume ratio 1:1), collected crystals, dissolved in ethanol, and dripped into a saturated ethanol solution of HCl to When pH=1, 6,7-methylenedioxy-1-(2-furylmethyl)-3,4-dihydroisoquinoline hydrochloride was obtained with a yield of 95.0% and a melting point of 204.2-205.0°C.

[0042] Elemental Analysis: C 15 h 14 ClNO 3 1 / 2H 2 O: Calculated %: C 59.90, H 5.02, N 4.66, Cl 11.79

[0043] Ex...

Embodiment 3

[0045] Example 3 6,7-methylenedioxy-1-(2-furylmethyl)-3,4-dihydroisoquinoline tartrate

[0046] Dissolve 2.59g (10mmol) N-2-furanoacetyl-3,4-methylenedioxyphenethylamine in 60ml benzene, add 1.5ml (15mmol) POCl dropwise 3 , the addition is complete, heated to 80 ° C, the reactant disappears (about 3 hours), and the excess POCl is evaporated under reduced pressure 3 and chloroform, the residue was washed with 1:1 benzene-hexane, solidified, and the crude product was collected by filtration, recrystallized from methanol-ether (volume ratio 1:1), and the crystals were collected to obtain 6,7-methylenedichloro-1 -(2-furylmethyl)-3,4-dihydroisoquinoline, dissolved in ethyl acetate, dropwise add saturated 8wt% tartaric acid ethyl acetate solution until pH=1.5, stir to precipitate crystals, filter , The filter cake was washed with ethyl acetate and dried to give 6,7-methylenedichloro-1-(2-furylmethyl)-3,4-dihydroisoquinoline tartrate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses isoquinolin compounds shown as a formula I and salts thereof. The invention also discloses a preparation method for the compounds, which comprises the step of reacting compounds shown as III under the action of a condensing agent in halogenated alkane or benzene. The invention also discloses a medicine composition containing the compounds, and application of the compounds to preparing medicines for treating arrhythmia. The isoquinolin compounds and the salts thereof have good antiarrhythmic activity and certain function of strengthening myocardial contraction force.

Description

technical field [0001] The present invention relates to a new compound, a pharmaceutical composition containing it, a preparation method and application thereof, in particular to an isoquinoline compound or a salt thereof, a pharmaceutical composition containing it, a preparation method and application thereof. Background technique [0002] Sudden cardiac death (SCD) is one of the leading causes of cardiovascular death. The generation of SCD is due to the instability of myocardial electrophysiology, which leads to the disappearance of regular heart rhythm, and the most serious ones are sustained ventricular tachycardia (VT, vetricular tachycardia) and ventricular fibrillation (VF, vetricalar fibrillation). [0003] At present, there are many antiarrhythmic drugs, such as sodium channel blockers, β-receptor blockers, calcium channel blockers, and potassium ion channel blockers. In clinical application, it is necessary for antiarrhythmic drugs to slow down the heart rate with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/04A61K31/4355A61P9/06
Inventor 魏建梅谢美华奚家瑞
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com